{"doc":{"info":{"calaisRequestID":"18851263-19cb-fd7f-15e8-c568cf8458c0","id":"http:\/\/id.opencalais.com\/8YPEQ-2c6TSqdbKGIDKTww","ontology":"http:\/\/mdaas-virtual-onecalais.int.thomsonreuters.com\/owlschema\/11.0\/onecalais.owl.allmetadata.xml","docId":"http:\/\/d.opencalais.com\/dochash-1\/99feba12-3692-32dc-b734-680545e54ff3","document":"FibroGen, Inc (NASDAQ:FGEN) VP Pat Cotroneo sold 2,851 shares of the business's stock in a transaction that occurred on Monday, September 11th. The shares were sold at an average price of $49.45, for a total transaction of $140,981.95. Following the completion of the sale, the vice president now owns 157,405 shares of the company's stock, valued at $7,783,677.25. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.\n\nPat Cotroneo also recently made the following trade(s):\n\nOn Tuesday, August 8th, Pat Cotroneo sold 95,000 shares of FibroGen stock. The shares were sold at an average price of $50.61, for a total transaction of $4,807,950.00. On Wednesday, August 2nd, Pat Cotroneo sold 28,346 shares of FibroGen stock. The shares were sold at an average price of $33.97, for a total transaction of $962,913.62. On Thursday, July 6th, Pat Cotroneo sold 4,000 shares of FibroGen stock. The shares were sold at an average price of $34.00, for a total transaction of $136,000.00. On Thursday, June 22nd, Pat Cotroneo sold 3,000 shares of FibroGen stock. The shares were sold at an average price of $32.00, for a total transaction of $96,000.00. On Monday, June 19th, Pat Cotroneo sold 5,500 shares of FibroGen stock. The shares were sold at an average price of $30.00, for a total transaction of $165,000.00.\n\nFibroGen, Inc (NASDAQ FGEN) opened at 52.40 on Friday. FibroGen, Inc has a 12 month low of $15.60 and a 12 month high of $52.70. The firm's 50-day moving average is $43.31 and its 200-day moving average is $32.07. The firm's market capitalization is $3.73 billion.\n\nFibroGen (NASDAQ:FGEN) last issued its earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.48) earnings per share for the quarter, missing analysts' consensus estimates of ($0.47) by ($0.01). The business had revenue of $29.00 million during the quarter, compared to analyst estimates of $34.80 million. FibroGen had a negative net margin of 105.59% and a negative return on equity of 64.42%. On average, equities research analysts expect that FibroGen, Inc will post ($1.80) EPS for the current year.\n\nTRADEMARK VIOLATION NOTICE: \"FibroGen, Inc (FGEN) VP Sells $140,981.95 in Stock\" was originally reported by Daily Political and is the sole property of of Daily Political. If you are accessing this news story on another website, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this news story can be read at https:\/\/www.dailypolitical.com\/2017\/09\/16\/fibrogen-inc-fgen-vp-sells-140981-95-in-stock.html.\n\nA number of equities research analysts recently issued reports on FGEN shares. Citigroup Inc. restated a \"buy\" rating and issued a $48.00 target price on shares of FibroGen in a report on Monday, June 26th. Jefferies Group LLC restated a \"buy\" rating and issued a $75.00 target price on shares of FibroGen in a report on Tuesday. Leerink Swann restated an \"outperform\" rating and issued a $82.00 target price (up from $52.00) on shares of FibroGen in a report on Tuesday, August 8th. BidaskClub upgraded shares of FibroGen from a \"buy\" rating to a \"strong-buy\" rating in a report on Saturday, June 24th. Finally, Goldman Sachs Group, Inc. (The) downgraded shares of FibroGen from a \"buy\" rating to a \"neutral\" rating and set a $31.00 target price for the company. in a report on Friday, July 21st. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, six have given a buy rating and one has issued a strong buy rating to the company's stock. The company presently has a consensus rating of \"Buy\" and an average target price of $60.17.\n\nInstitutional investors and hedge funds have recently modified their holdings of the company. Ameritas Investment Partners Inc. acquired a new position in shares of FibroGen in the 1st quarter valued at about $111,000. Quantbot Technologies LP acquired a new position in shares of FibroGen in the 2nd quarter valued at about $128,000. SG Americas Securities LLC increased its holdings in shares of FibroGen by 6.5% in the 2nd quarter. SG Americas Securities LLC now owns 6,747 shares of the biopharmaceutical company's stock valued at $218,000 after purchasing an additional 412 shares during the period. Airain ltd acquired a new position in shares of FibroGen in the 1st quarter valued at about $236,000. Finally, Amalgamated Bank acquired a new position in shares of FibroGen in the 2nd quarter valued at about $237,000. Institutional investors own 47.49% of the company's stock.\n\nAbout FibroGen\n\nFibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.\n\nReceive News & Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related companies with MarketBeat.com's FREE daily email newsletter.","docTitle":"","docDate":"2017-09-16 20:17:16.825"},"meta":{"contentType":"text\/raw","processingVer":"AllMetadata","serverVersion":"OneCalais_11.0-RELEASE:169","stagsVer":"OneCalais_11.0-RELEASE-b10-2017-07-31_12:36:53","submissionDate":"2017-09-16 20:17:16.024","submitterCode":"0ca6a864-5659-789d-5f32-f365f695e757","signature":"digestalg-1|9vThkoJG3nAAYdBS7L7eMhjTMtI=|jKb2v53tXLo54On7jSUtq6yyfKqI\/3m0jlqTNIpxeWZ3k4avb5AsUw==","language":"English"}},"http:\/\/d.opencalais.com\/dochash-1\/99feba12-3692-32dc-b734-680545e54ff3\/cat\/1":{"_typeGroup":"topics","forenduserdisplay":"false","score":1,"name":"Business_Finance"},"http:\/\/d.opencalais.com\/dochash-1\/99feba12-3692-32dc-b734-680545e54ff3\/lid\/DefaultLangId":{"_typeGroup":"language","language":"http:\/\/d.opencalais.com\/lid\/DefaultLangId\/English","forenduserdisplay":"false","permid":"505062"},"http:\/\/d.opencalais.com\/dochash-1\/99feba12-3692-32dc-b734-680545e54ff3\/SocialTag\/1":{"_typeGroup":"socialTag","id":"http:\/\/d.opencalais.com\/dochash-1\/99feba12-3692-32dc-b734-680545e54ff3\/SocialTag\/1","socialTag":"http:\/\/d.opencalais.com\/genericHasher-1\/acd44d54-d8f3-3c36-a78c-2da2af5a2ae8","forenduserdisplay":"true","name":"Finance","importance":"1","originalValue":"Finance"},"http:\/\/d.opencalais.com\/dochash-1\/99feba12-3692-32dc-b734-680545e54ff3\/SocialTag\/2":{"_typeGroup":"socialTag","id":"http:\/\/d.opencalais.com\/dochash-1\/99feba12-3692-32dc-b734-680545e54ff3\/SocialTag\/2","socialTag":"http:\/\/d.opencalais.com\/genericHasher-1\/f1af9688-5498-363e-9052-be898dce559c","forenduserdisplay":"true","name":"Money","importance":"1","originalValue":"Money"},"http:\/\/d.opencalais.com\/dochash-1\/99feba12-3692-32dc-b734-680545e54ff3\/SocialTag\/3":{"_typeGroup":"socialTag","id":"http:\/\/d.opencalais.com\/dochash-1\/99feba12-3692-32dc-b734-680545e54ff3\/SocialTag\/3","socialTag":"http:\/\/d.opencalais.com\/genericHasher-1\/56bb9859-75e0-3b28-acdb-61f6b786cc4c","forenduserdisplay":"true","name":"Financial economics","importance":"1","originalValue":"Financial economics"},"http:\/\/d.opencalais.com\/dochash-1\/99feba12-3692-32dc-b734-680545e54ff3\/SocialTag\/4":{"_typeGroup":"socialTag","id":"http:\/\/d.opencalais.com\/dochash-1\/99feba12-3692-32dc-b734-680545e54ff3\/SocialTag\/4","socialTag":"http:\/\/d.opencalais.com\/genericHasher-1\/06fb4dfb-0f17-320f-a936-8a3d8807cef9","forenduserdisplay":"true","name":"Stock market","importance":"2","originalValue":"Stock market"},"http:\/\/d.opencalais.com\/dochash-1\/99feba12-3692-32dc-b734-680545e54ff3\/SocialTag\/5":{"_typeGroup":"socialTag","id":"http:\/\/d.opencalais.com\/dochash-1\/99feba12-3692-32dc-b734-680545e54ff3\/SocialTag\/5","socialTag":"http:\/\/d.opencalais.com\/genericHasher-1\/e50a3117-017a-3d4d-9ce6-3238cb5db16c","forenduserdisplay":"true","name":"Equity securities","importance":"2","originalValue":"Equity securities"},"http:\/\/d.opencalais.com\/dochash-1\/99feba12-3692-32dc-b734-680545e54ff3\/SocialTag\/6":{"_typeGroup":"socialTag","id":"http:\/\/d.opencalais.com\/dochash-1\/99feba12-3692-32dc-b734-680545e54ff3\/SocialTag\/6","socialTag":"http:\/\/d.opencalais.com\/genericHasher-1\/320d970c-7030-327c-afdf-f56494e4c636","forenduserdisplay":"true","name":"Financial regulation","importance":"2","originalValue":"Financial regulation"},"http:\/\/d.opencalais.com\/dochash-1\/99feba12-3692-32dc-b734-680545e54ff3\/SocialTag\/7":{"_typeGroup":"socialTag","id":"http:\/\/d.opencalais.com\/dochash-1\/99feba12-3692-32dc-b734-680545e54ff3\/SocialTag\/7","socialTag":"http:\/\/d.opencalais.com\/genericHasher-1\/9e26f604-2835-38e4-b94c-99376a7f18a7","forenduserdisplay":"true","name":"Economic history of the Netherlands","importance":"2","originalValue":"Economic history of the Netherlands"},"http:\/\/d.opencalais.com\/dochash-1\/99feba12-3692-32dc-b734-680545e54ff3\/SocialTag\/8":{"_typeGroup":"socialTag","id":"http:\/\/d.opencalais.com\/dochash-1\/99feba12-3692-32dc-b734-680545e54ff3\/SocialTag\/8","socialTag":"http:\/\/d.opencalais.com\/genericHasher-1\/e3bed591-ad6d-30db-b70a-c02c5ae755bd","forenduserdisplay":"true","name":"Corporate finance","importance":"2","originalValue":"Corporate finance"},"http:\/\/d.opencalais.com\/dochash-1\/99feba12-3692-32dc-b734-680545e54ff3\/SocialTag\/9":{"_typeGroup":"socialTag","id":"http:\/\/d.opencalais.com\/dochash-1\/99feba12-3692-32dc-b734-680545e54ff3\/SocialTag\/9","socialTag":"http:\/\/d.opencalais.com\/genericHasher-1\/888c2b1b-c1a6-34fe-a071-d99538e65465","forenduserdisplay":"true","name":"Stock","importance":"2","originalValue":"Stock"},"http:\/\/d.opencalais.com\/dochash-1\/99feba12-3692-32dc-b734-680545e54ff3\/SocialTag\/10":{"_typeGroup":"socialTag","id":"http:\/\/d.opencalais.com\/dochash-1\/99feba12-3692-32dc-b734-680545e54ff3\/SocialTag\/10","socialTag":"http:\/\/d.opencalais.com\/genericHasher-1\/68176a81-75ce-36b6-8940-f6a805b4b409","forenduserdisplay":"true","name":"Short","importance":"2","originalValue":"Short (finance)"},"http:\/\/d.opencalais.com\/dochash-1\/99feba12-3692-32dc-b734-680545e54ff3\/SocialTag\/11":{"_typeGroup":"socialTag","id":"http:\/\/d.opencalais.com\/dochash-1\/99feba12-3692-32dc-b734-680545e54ff3\/SocialTag\/11","socialTag":"http:\/\/d.opencalais.com\/genericHasher-1\/cce03b5b-3505-3e73-a55d-b5bed41b226e","forenduserdisplay":"true","name":"Share","importance":"2","originalValue":"Share (finance)"},"http:\/\/d.opencalais.com\/dochash-1\/99feba12-3692-32dc-b734-680545e54ff3\/SocialTag\/12":{"_typeGroup":"socialTag","id":"http:\/\/d.opencalais.com\/dochash-1\/99feba12-3692-32dc-b734-680545e54ff3\/SocialTag\/12","socialTag":"http:\/\/d.opencalais.com\/genericHasher-1\/a6d27ed2-a3fe-3b4a-848b-eb57b4458113","forenduserdisplay":"true","name":"NASDAQ","importance":"2","originalValue":"NASDAQ"},"http:\/\/d.opencalais.com\/dochash-1\/99feba12-3692-32dc-b734-680545e54ff3\/Industry\/1":{"_typeGroup":"industry","forenduserdisplay":"false","name":"Corporate Financial Services - NEC","rcscode":"B:1627","permid":"4294951374","relevance":0.5},"http:\/\/d.opencalais.com\/dochash-1\/99feba12-3692-32dc-b734-680545e54ff3\/Industry\/2":{"_typeGroup":"industry","forenduserdisplay":"false","name":"Banks - NEC","rcscode":"B:1615","permid":"4294951386","relevance":0.5},"http:\/\/d.opencalais.com\/dochash-1\/99feba12-3692-32dc-b734-680545e54ff3\/Industry\/3":{"_typeGroup":"industry","forenduserdisplay":"false","name":"Biotechnology & Medical Research - NEC","rcscode":"B:1736","permid":"4294951265","relevance":0.8},"http:\/\/d.opencalais.com\/dochash-1\/99feba12-3692-32dc-b734-680545e54ff3\/Industry\/4":{"_typeGroup":"industry","forenduserdisplay":"false","name":"Investment Banking","rcscode":"B:1634","permid":"4294951367","relevance":0.2},"http:\/\/d.opencalais.com\/dochash-1\/99feba12-3692-32dc-b734-680545e54ff3\/Industry\/5":{"_typeGroup":"industry","forenduserdisplay":"false","name":"Investment Banking & Brokerage Services - NEC","rcscode":"B:1633","permid":"4294951368","relevance":0.5},"http:\/\/d.opencalais.com\/dochash-1\/99feba12-3692-32dc-b734-680545e54ff3\/Industry\/6":{"_typeGroup":"industry","forenduserdisplay":"false","name":"Diversified Investment Services","rcscode":"B:1647","permid":"4294951354","relevance":0.5},"http:\/\/d.opencalais.com\/dochash-1\/99feba12-3692-32dc-b734-680545e54ff3\/ComponentVersions":{"_typeGroup":"versions","version":["DIY-Categorization-fnr-TRCS-capx:20170627191152:20170627191152","Deals Index:201709161945:201709161945","DIY-Categorization-fnr-TRCS-indx_stsale:20170323110805:20170323110805","DIY-Categorization-fnr-TRCS-comptn:20170621141739:20170621141739","index-refineries:201705201529:201705201529","DIY-Categorization-fnr-TRCS-regs_buyb_new:20170509091609:20170509091609","config-physicalAssets-powerStations:653:653","NextTags:OneCalais_11.0-RELEASE:169","DIY-Categorization-fnr-TRCS-dis:20170418132337:20170418132337","DIY-Categorization-fnr-TRCS-splitb_r1:20170329082516:20170329082516","config-sca-DataPackage:50:50","config-companyNe:655:655","DIY-Categorization-fnr-TRCS-acb:20170502102348:20170502102348","DIY-Categorization-fnr-TRCS-levrge:20170621122109:20170621122109","DIY-Categorization-fnr-TRCS-hedge_list1:20170315123823:20170315123823","config-refreshableDIY:1:1","People Index:201709161805:201709161805","DIY-Categorization-fnr-TRCS-awlq:20170331124441:20170331124441","config-negativeSignature:653:653","DIY-Categorization-fnr-TRCS-fake1_monop_bnkcap_new:20170405133257:20170405133257","Dial4J:OneCalais_8.6-RELEASE:209","DIY-Categorization-fnr-TRCS-dbtr_new:20170315123740:20170315123740","OA Override:672:672","DIY-Categorization-fnr-TRCS-hrgt:20170427081548:20170427081548","DIY-Categorization-fnr-TRCS-xpand:20170323144646:20170323144646","DIY-Categorization-fnr-TRCS-allcemrgdvst2:20170316142831:20170316142831","DIY-Categorization-fnr-TRCS-ordr:20170313151239:20170313151239","People Override:653:653","DIY-Categorization-fnr-TRCS-hrgt_recll:20170522120000:20170522120000","index-company-oa3:201709152235:201709152235","index-vessels:201709100045:201709100045","DIY-Categorization-fnr-TRCS-brib_r1:20170329090629:20170329090629","config-forEndUserDisplay:3:3","config-refineries:653:653","DIY-Categorization-fnr-TRCS-fapm:20170713144316:20170713144316","DIY-Categorization-fnr-TRCS-class:20170315123207:20170315123207","config-cse:672:672","DIY-Categorization-fnr-TRCS-isu_dat_r:20170315124144:20170315124144","DIY-Categorization-fnr-TRCS-cnsl_sisu:20170321144134:20170321144134","DIY-Categorization-fnr-TRCS-shract_r1:20170412111808:20170412111808","config-vessels:653:653","OneCalais:OneCalais_11.0-RELEASE:169","DIY-Categorization-fnr-TRCS-mktshr2:20170705120412:20170705120412","DIY-RCS-fnr-TRCS-cavs:4:4","DIY-Categorization-fnr-TRCS-trd_tax:20170309132522:20170309132522","DIY-Categorization-fnr-TRCS-sov_2:20170522130956:20170522130956","DIY-Categorization-fnr-TRCS-bons:20170406103713:20170406103713","DIY-Categorization-fnr-TRCS-hrgt_namec:20170329090731:20170329090731","DIY-RCS-fnr-TRCS-nd:3:3","DIY-Categorization-fnr-TRCS-stx:20170530123138:20170530123138","config-physicalAssets-mines:653:653","SocialTags Index:201709031835:201709031835","BlackList:672:672","index-ports:201709091840:201709091840","config-physicalAssets-ports:653:653","DIY-Categorization-fnr-TRCS-ream:20170529065740:20170529065740","DIY-Categorization-fnr-TRCS-chld:20170524084254:20170524084254","DIY-Categorization-fnr-TRCS-allce:20170323145654:20170323145654","DIY-Categorization-fnr-TRCS-medreg:20170508120210:20170508120210","config-drugs:653:653"]},"http:\/\/d.opencalais.com\/comphash-1\/5e2ac775-3229-336a-97ea-8c22044c7324":{"_typeGroup":"entities","_type":"Company","forenduserdisplay":"true","name":"FibroGen Inc","nationality":"N\/A","confidencelevel":"1.0","_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/e\/Company","instances":[{"detection":"[]FibroGen, Inc (NASDAQ:FGEN)[ VP Pat Cotroneo sold 2,851 shares of the]","exact":"FibroGen, Inc (NASDAQ:FGEN)","suffix":" VP Pat Cotroneo sold 2,851 shares of the","offset":0,"length":27},{"detection":"[August 8th, Pat Cotroneo sold 95,000 shares of ]FibroGen[ stock. The shares were sold at an average price]","prefix":"August 8th, Pat Cotroneo sold 95,000 shares of ","exact":"FibroGen","suffix":" stock. The shares were sold at an average price","offset":619,"length":8},{"detection":"[August 2nd, Pat Cotroneo sold 28,346 shares of ]FibroGen[ stock. The shares were sold at an average price]","prefix":"August 2nd, Pat Cotroneo sold 28,346 shares of ","exact":"FibroGen","suffix":" stock. The shares were sold at an average price","offset":790,"length":8},{"detection":"[July 6th, Pat Cotroneo sold 4,000 shares of ]FibroGen[ stock. The shares were sold at an average price]","prefix":"July 6th, Pat Cotroneo sold 4,000 shares of ","exact":"FibroGen","suffix":" stock. The shares were sold at an average price","offset":955,"length":8},{"detection":"[June 22nd, Pat Cotroneo sold 3,000 shares of ]FibroGen[ stock. The shares were sold at an average price]","prefix":"June 22nd, Pat Cotroneo sold 3,000 shares of ","exact":"FibroGen","suffix":" stock. The shares were sold at an average price","offset":1121,"length":8},{"detection":"[June 19th, Pat Cotroneo sold 5,500 shares of ]FibroGen[ stock. The shares were sold at an average price]","prefix":"June 19th, Pat Cotroneo sold 5,500 shares of ","exact":"FibroGen","suffix":" stock. The shares were sold at an average price","offset":1284,"length":8},{"detection":"[ $30.00, for a total transaction of $165,000.00.\n\n]FibroGen, Inc[ (NASDAQ FGEN) opened at 52.40 on Friday.]","prefix":" $30.00, for a total transaction of $165,000.00.\n\n","exact":"FibroGen, Inc","suffix":" (NASDAQ FGEN) opened at 52.40 on Friday.","offset":1393,"length":13},{"detection":"[of $165,000.00.\n\nFibroGen, Inc (NASDAQ ]FGEN[) opened at 52.40 on Friday. FibroGen, Inc has a]","prefix":"of $165,000.00.\n\nFibroGen, Inc (NASDAQ ","exact":"FGEN","suffix":") opened at 52.40 on Friday. FibroGen, Inc has a","offset":1415,"length":4},{"detection":"[Inc (NASDAQ FGEN) opened at 52.40 on Friday. ]FibroGen, Inc[ has a 12 month low of $15.60 and a 12 month high]","prefix":"Inc (NASDAQ FGEN) opened at 52.40 on Friday. ","exact":"FibroGen, Inc","suffix":" has a 12 month low of $15.60 and a 12 month high","offset":1448,"length":13},{"detection":"[firm's market capitalization is $3.73 billion.\n\n]FibroGen (NASDAQ:FGEN)[ last issued its earnings results on Monday,]","prefix":"firm's market capitalization is $3.73 billion.\n\n","exact":"FibroGen (NASDAQ:FGEN)","suffix":" last issued its earnings results on Monday,","offset":1659,"length":22},{"detection":"[ compared to analyst estimates of $34.80 million. ]FibroGen[ had a negative net margin of 105.59% and a]","prefix":" compared to analyst estimates of $34.80 million. ","exact":"FibroGen","suffix":" had a negative net margin of 105.59% and a","offset":1994,"length":8},{"detection":"[average, equities research analysts expect that ]FibroGen, Inc[ will post ($1.80) EPS for the current]","prefix":"average, equities research analysts expect that ","exact":"FibroGen, Inc","suffix":" will post ($1.80) EPS for the current","offset":2134,"length":13},{"detection":"[the current year.\n\nTRADEMARK VIOLATION NOTICE: \"]FibroGen, Inc (FGEN)[ VP Sells $140,981.95 in Stock\" was originally]","prefix":"the current year.\n\nTRADEMARK VIOLATION NOTICE: \"","exact":"FibroGen, Inc (FGEN)","suffix":" VP Sells $140,981.95 in Stock\" was originally","offset":2222,"length":20},{"detection":"[research analysts recently issued reports on ]FGEN[ shares. Citigroup Inc. restated a \"buy\" rating]","prefix":"research analysts recently issued reports on ","exact":"FGEN","suffix":" shares. Citigroup Inc. restated a \"buy\" rating","offset":2750,"length":4},{"detection":"[and issued a $48.00 target price on shares of ]FibroGen[ in a report on Monday, June 26th. Jefferies]","prefix":"and issued a $48.00 target price on shares of ","exact":"FibroGen","suffix":" in a report on Monday, June 26th. Jefferies","offset":2848,"length":8},{"detection":"[and issued a $75.00 target price on shares of ]FibroGen[ in a report on Tuesday. Leerink Swann restated]","prefix":"and issued a $75.00 target price on shares of ","exact":"FibroGen","suffix":" in a report on Tuesday. Leerink Swann restated","offset":2981,"length":8},{"detection":"[target price (up from $52.00) on shares of ]FibroGen[ in a report on Tuesday, August 8th. BidaskClub]","prefix":"target price (up from $52.00) on shares of ","exact":"FibroGen","suffix":" in a report on Tuesday, August 8th. BidaskClub","offset":3123,"length":8},{"detection":"[August 8th. BidaskClub upgraded shares of ]FibroGen[ from a \"buy\" rating to a \"strong-buy\" rating in]","prefix":"August 8th. BidaskClub upgraded shares of ","exact":"FibroGen","suffix":" from a \"buy\" rating to a \"strong-buy\" rating in","offset":3198,"length":8},{"detection":"[Sachs Group, Inc. (The) downgraded shares of ]FibroGen[ from a \"buy\" rating to a \"neutral\" rating and]","prefix":"Sachs Group, Inc. (The) downgraded shares of ","exact":"FibroGen","suffix":" from a \"buy\" rating to a \"neutral\" rating and","offset":3350,"length":8},{"detection":"[Inc. acquired a new position in shares of ]FibroGen[ in the 1st quarter valued at about $111,000.]","prefix":"Inc. acquired a new position in shares of ","exact":"FibroGen","suffix":" in the 1st quarter valued at about $111,000.","offset":3925,"length":8},{"detection":"[LP acquired a new position in shares of ]FibroGen[ in the 2nd quarter valued at about $128,000. SG]","prefix":"LP acquired a new position in shares of ","exact":"FibroGen","suffix":" in the 2nd quarter valued at about $128,000. SG","offset":4041,"length":8},{"detection":"[LLC increased its holdings in shares of ]FibroGen[ by 6.5% in the 2nd quarter. SG Americas]","prefix":"LLC increased its holdings in shares of ","exact":"FibroGen","suffix":" by 6.5% in the 2nd quarter. SG Americas","offset":4158,"length":8},{"detection":"[Airain ltd acquired a new position in shares of ]FibroGen[ in the 1st quarter valued at about $236,000.]","prefix":"Airain ltd acquired a new position in shares of ","exact":"FibroGen","suffix":" in the 1st quarter valued at about $236,000.","offset":4413,"length":8},{"detection":"[Bank acquired a new position in shares of ]FibroGen[ in the 2nd quarter valued at about $237,000.]","prefix":"Bank acquired a new position in shares of ","exact":"FibroGen","suffix":" in the 2nd quarter valued at about $237,000.","offset":4530,"length":8},{"detection":"[own 47.49% of the company's stock.\n\nAbout ]FibroGen[\n\nFibroGen, Inc is a science-based]","prefix":"own 47.49% of the company's stock.\n\nAbout ","exact":"FibroGen","suffix":"\n\nFibroGen, Inc is a science-based","offset":4650,"length":8},{"detection":"[47.49% of the company's stock.\n\nAbout FibroGen\n\n]FibroGen, Inc[ is a science-based biopharmaceutical company]","prefix":"47.49% of the company's stock.\n\nAbout FibroGen\n\n","exact":"FibroGen, Inc","suffix":" is a science-based biopharmaceutical company","offset":4660,"length":13},{"detection":"[ disease, and cancer.\n\nReceive News & Ratings for ]FibroGen Inc[ Daily - Enter your email address below to]","prefix":" disease, and cancer.\n\nReceive News & Ratings for ","exact":"FibroGen Inc","suffix":" Daily - Enter your email address below to","offset":5012,"length":12},{"detection":"[of the latest news and analysts' ratings for ]FibroGen Inc[ and related companies with MarketBeat.com's FREE]","prefix":"of the latest news and analysts' ratings for ","exact":"FibroGen Inc","suffix":" and related companies with MarketBeat.com's FREE","offset":5144,"length":12}],"relevance":0.8,"confidence":{"statisticalfeature":"0.99","dblookup":"0.0","resolution":"0.97074527","aggregate":"1.0"},"resolutions":[{"name":"FIBROGEN, INC.","permid":"4296495572","primaryric":"FGEN.OQ","ispublic":"true","commonname":"FibroGen","score":0.97074527,"id":"https:\/\/permid.org\/1-4296495572","ticker":"FGEN"}]},"http:\/\/d.opencalais.com\/genericHasher-1\/a634c1bf-cb35-33ba-8d76-398412255cec":{"_typeGroup":"entities","_type":"Position","forenduserdisplay":"false","name":"VP Sells","_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/e\/Position","instances":[{"detection":"[VIOLATION NOTICE: \"FibroGen, Inc (FGEN) ]VP Sells[ $140,981.95 in Stock\" was originally reported by]","prefix":"VIOLATION NOTICE: \"FibroGen, Inc (FGEN) ","exact":"VP Sells","suffix":" $140,981.95 in Stock\" was originally reported by","offset":2243,"length":8}],"relevance":0.2},"http:\/\/d.opencalais.com\/comphash-1\/f4a56cd2-94d5-3c7a-8058-1b7297309d15":{"_typeGroup":"entities","_type":"Company","forenduserdisplay":"true","name":"Goldman Sachs Group Inc.","nationality":"N\/A","confidencelevel":"0.999","_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/e\/Company","instances":[{"detection":"[in a report on Saturday, June 24th. Finally, ]Goldman Sachs Group, Inc.[ (The) downgraded shares of FibroGen from a \"buy\"]","prefix":"in a report on Saturday, June 24th. Finally, ","exact":"Goldman Sachs Group, Inc.","suffix":" (The) downgraded shares of FibroGen from a \"buy\"","offset":3297,"length":25}],"relevance":0,"resolutions":[{"name":"THE GOLDMAN SACHS GROUP, INC.","permid":"4295911963","primaryric":"GS.N","ispublic":"true","commonname":"Goldman Sachs","score":0.9885544,"id":"https:\/\/permid.org\/1-4295911963","ticker":"GS"}],"confidence":{"statisticalfeature":"0.999","dblookup":"0.0","resolution":"0.9885544","aggregate":"0.999"}},"http:\/\/d.opencalais.com\/comphash-1\/241f9ea9-fd9e-3e6e-a476-a34634ff5791":{"_typeGroup":"entities","_type":"Company","forenduserdisplay":"true","name":"Ameritas Investment Partners Inc.","nationality":"N\/A","confidencelevel":"1.0","resolutions":[{"name":"AMERITAS INVESTMENT PARTNERS, INC.","permid":"5035463116","ispublic":"false","commonname":"Ameritas Invest","score":0.2139226,"id":"https:\/\/permid.org\/1-5035463116"}],"_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/e\/Company","instances":[{"detection":"[ recently modified their holdings of the company. ]Ameritas Investment Partners Inc.[ acquired a new position in shares of FibroGen in]","prefix":" recently modified their holdings of the company. ","exact":"Ameritas Investment Partners Inc.","suffix":" acquired a new position in shares of FibroGen in","offset":3854,"length":33}],"relevance":0.5,"confidence":{"statisticalfeature":"0.842","dblookup":"0.0","resolution":"0.2139226","aggregate":"1.0"}},"http:\/\/d.opencalais.com\/genericHasher-1\/4a28bb64-6c02-32f2-98ea-5851f27aaced":{"_typeGroup":"entities","_type":"Position","forenduserdisplay":"false","name":"VP","_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/e\/Position","instances":[{"detection":"[FibroGen, Inc (NASDAQ:FGEN) ]VP[ Pat Cotroneo sold 2,851 shares of the business's]","prefix":"FibroGen, Inc (NASDAQ:FGEN) ","exact":"VP","suffix":" Pat Cotroneo sold 2,851 shares of the business's","offset":28,"length":2}],"relevance":0.2},"http:\/\/d.opencalais.com\/comphash-1\/2bc5f957-060d-3bf0-908c-8379fdbca2e7":{"_typeGroup":"entities","_type":"Company","forenduserdisplay":"true","name":"Amalgamated Bank","nationality":"N\/A","confidencelevel":"1.0","_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/e\/Company","instances":[{"detection":"[1st quarter valued at about $236,000. Finally, ]Amalgamated Bank[ acquired a new position in shares of FibroGen in]","prefix":"1st quarter valued at about $236,000. Finally, ","exact":"Amalgamated Bank","suffix":" acquired a new position in shares of FibroGen in","offset":4476,"length":16}],"relevance":0.5,"confidence":{"statisticalfeature":"0.732","dblookup":"0.0","resolution":"0.095862806","aggregate":"1.0"},"resolutions":[{"name":"AMALGAMATED BANK","permid":"4297404958","ispublic":"false","commonname":"Amalgamated Bank","score":0.095862806,"id":"https:\/\/permid.org\/1-4297404958"}]},"http:\/\/d.opencalais.com\/genericHasher-1\/dfa77724-36a9-3567-b809-c2b171a4518a":{"_typeGroup":"entities","_type":"IndustryTerm","forenduserdisplay":"false","name":"biopharmaceutical","_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/e\/IndustryTerm","instances":[{"detection":"[its earnings results on Monday, August 7th. The ]biopharmaceutical company[ reported ($0.48) earnings per share for the]","prefix":"its earnings results on Monday, August 7th. The ","exact":"biopharmaceutical company","suffix":" reported ($0.48) earnings per share for the","offset":1742,"length":25},{"detection":"[Securities LLC now owns 6,747 shares of the ]biopharmaceutical company['s stock valued at $218,000 after purchasing an]","prefix":"Securities LLC now owns 6,747 shares of the ","exact":"biopharmaceutical company","suffix":"'s stock valued at $218,000 after purchasing an","offset":4251,"length":25}],"relevance":0.2},"http:\/\/d.opencalais.com\/comphash-1\/38447cbc-6c26-3090-9960-2b4882fa1dae":{"_typeGroup":"entities","_type":"Company","forenduserdisplay":"true","name":"Quantbot Technologies LP","nationality":"N\/A","confidencelevel":"1.0","confidence":{"statisticalfeature":"0.834","dblookup":"0.0","resolution":"0.075219676","aggregate":"1.0"},"_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/e\/Company","instances":[{"detection":"[in the 1st quarter valued at about $111,000. ]Quantbot Technologies LP[ acquired a new position in shares of FibroGen in]","prefix":"in the 1st quarter valued at about $111,000. ","exact":"Quantbot Technologies LP","suffix":" acquired a new position in shares of FibroGen in","offset":3979,"length":24}],"relevance":0.5,"resolutions":[{"name":"QUANTBOT TECHNOLOGIES, LP","permid":"5036348924","ispublic":"false","commonname":"Quantbot Tech","score":0.075219676,"id":"https:\/\/permid.org\/1-5036348924"}]},"http:\/\/d.opencalais.com\/genericHasher-1\/aade7447-58e7-353d-9e5d-b0e79e2a6639":{"_typeGroup":"entities","_type":"IndustryTerm","forenduserdisplay":"false","name":"treatment of anemia, fibrotic disease","_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/e\/IndustryTerm","instances":[{"detection":"[to advance innovative medicines for the ]treatment of anemia, fibrotic disease[, and cancer.\n\nReceive News & Ratings for]","prefix":"to advance innovative medicines for the ","exact":"treatment of anemia, fibrotic disease","suffix":", and cancer.\n\nReceive News & Ratings for","offset":4933,"length":37}],"relevance":0.2},"http:\/\/d.opencalais.com\/comphash-1\/55eeb653-ab9e-3561-b237-0500aeb5e39f":{"_typeGroup":"entities","_type":"Company","forenduserdisplay":"true","name":"Airain ltd","confidencelevel":"1.0","_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/e\/Company","instances":[{"detection":"[an additional 412 shares during the period. ]Airain ltd[ acquired a new position in shares of FibroGen in]","prefix":"an additional 412 shares during the period. ","exact":"Airain ltd","suffix":" acquired a new position in shares of FibroGen in","offset":4365,"length":10}],"relevance":0.5,"resolutions":[{"name":"Airain Limited","permid":"5038069811","ispublic":"false","commonname":"Airain","score":0.40809628,"id":"https:\/\/permid.org\/1-5038069811"}],"confidence":{"statisticalfeature":"0.668","dblookup":"0.0","resolution":"0.40809628","aggregate":"1.0"}},"http:\/\/d.opencalais.com\/genericHasher-1\/a54ac18b-a956-3b5c-b235-0609ca899305":{"_typeGroup":"entities","_type":"Country","forenduserdisplay":"true","name":"United States","_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/e\/Country","instances":[{"detection":"[copied illegally and reposted in violation of ]United States[ and international trademark & copyright law. The]","prefix":"copied illegally and reposted in violation of ","exact":"United States","suffix":" and international trademark & copyright law. The","offset":2475,"length":13}],"relevance":0.2,"resolutions":[{"name":"United States","shortname":"United States","latitude":"40.4230003233","longitude":"-98.7372244786","rcscode":"G:6J","permid":"100319"}]},"http:\/\/d.opencalais.com\/genericHasher-1\/082e2433-7eb7-3905-b3fb-d5c2ece093d0":{"_typeGroup":"entities","_type":"Position","forenduserdisplay":"false","name":"vice president","_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/e\/Position","instances":[{"detection":"[Following the completion of the sale, ]the vice president[ now owns 157,405 shares of the company's stock,]","prefix":"Following the completion of the sale, ","exact":"the vice president","suffix":" now owns 157,405 shares of the company's stock,","offset":274,"length":18}],"relevance":0.2},"http:\/\/d.opencalais.com\/genericHasher-1\/7ca3499c-033d-33aa-8ad4-17ed427a99d3":{"_typeGroup":"entities","_type":"IndustryTerm","forenduserdisplay":"false","name":"copyright law","_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/e\/IndustryTerm","instances":[{"detection":"[of United States and international trademark & ]copyright law[. The original version of this news story can be]","prefix":"of United States and international trademark & ","exact":"copyright law","suffix":". The original version of this news story can be","offset":2519,"length":13}],"relevance":0.2},"http:\/\/d.opencalais.com\/genericHasher-1\/1b161d51-fe16-3261-a87e-1c36ffa59f6b":{"_typeGroup":"entities","_type":"Position","forenduserdisplay":"false","name":"research analyst","_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/e\/Position","instances":[{"detection":"[company. in a report on Friday, July 21st. One ]research analyst[ has rated the stock with a sell rating, one has]","prefix":"company. in a report on Friday, July 21st. One ","exact":"research analyst","suffix":" has rated the stock with a sell rating, one has","offset":3486,"length":16}],"relevance":0.2},"http:\/\/d.opencalais.com\/comphash-1\/620a0215-3ca2-32a7-9ca8-db2dbd7551a1":{"_typeGroup":"entities","_type":"Company","forenduserdisplay":"false","name":"Leerink Swann","nationality":"N\/A","confidencelevel":"0.732","confidence":{"statisticalfeature":"0.815","dblookup":"0.0","resolution":"0.11554771","aggregate":"0.732"},"_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/e\/Company","instances":[{"detection":"[on shares of FibroGen in a report on Tuesday. ]Leerink Swann[ restated an \"outperform\" rating and issued a]","prefix":"on shares of FibroGen in a report on Tuesday. ","exact":"Leerink Swann","suffix":" restated an \"outperform\" rating and issued a","offset":3014,"length":13}],"relevance":0.2,"resolutions":[{"name":"LEERINK SWANN HOLDINGS, LLC","permid":"5000779140","ispublic":"false","commonname":"Leerink Swann","score":0.11554771,"id":"https:\/\/permid.org\/1-5000779140"}]},"http:\/\/d.opencalais.com\/genericHasher-1\/b393938a-d8aa-3a58-b2ef-f0a6547c9150":{"_typeGroup":"entities","_type":"IndustryTerm","forenduserdisplay":"false","name":"science-based biopharmaceutical","_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/e\/IndustryTerm","instances":[{"detection":"[stock.\n\nAbout FibroGen\n\nFibroGen, Inc is a ]science-based biopharmaceutical company[ discovering and developing a pipeline of first-]","prefix":"stock.\n\nAbout FibroGen\n\nFibroGen, Inc is a ","exact":"science-based biopharmaceutical company","suffix":" discovering and developing a pipeline of first-","offset":4679,"length":39}],"relevance":0.2},"http:\/\/d.opencalais.com\/genericHasher-1\/a12b43d5-d195-35ea-96a9-f710943bdb5a":{"_typeGroup":"entities","_type":"Position","forenduserdisplay":"false","name":"analyst","_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/e\/Position","instances":[{"detection":"[$29.00 million during the quarter, compared to ]analyst[ estimates of $34.80 million. FibroGen had a]","prefix":"$29.00 million during the quarter, compared to ","exact":"analyst","suffix":" estimates of $34.80 million. FibroGen had a","offset":1957,"length":7}],"relevance":0.2},"http:\/\/d.opencalais.com\/genericHasher-1\/2295f9a6-80a6-36b0-a87f-2240d88f55e4":{"_typeGroup":"entities","_type":"Organization","forenduserdisplay":"false","name":"Securities & Exchange Commission","organizationtype":"governmental civilian","nationality":"N\/A","_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/e\/Organization","permid":"https:\/\/permid.org\/1-404010","instances":[{"detection":"[was disclosed in a legal filing with the ]Securities & Exchange Commission[, which is accessible through the SEC]","prefix":"was disclosed in a legal filing with the ","exact":"Securities & Exchange Commission","suffix":", which is accessible through the SEC","offset":423,"length":32},{"detection":"[Commission, which is accessible through the ]SEC[ website.\n\nPat Cotroneo also recently made the]","prefix":"Commission, which is accessible through the ","exact":"SEC","suffix":" website.\n\nPat Cotroneo also recently made the","offset":489,"length":3}],"relevance":0.2},"http:\/\/d.opencalais.com\/comphash-1\/335530be-bab7-3443-833d-31057e4a7839":{"_typeGroup":"entities","_type":"Company","forenduserdisplay":"true","name":"Citigroup Inc.","nationality":"N\/A","confidencelevel":"1.0","resolutions":[{"name":"CITIGROUP INC.","permid":"8589934316","primaryric":"C.N","ispublic":"true","commonname":"Citigroup","score":0.95025086,"id":"https:\/\/permid.org\/1-8589934316","ticker":"C"}],"_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/e\/Company","instances":[{"detection":"[ analysts recently issued reports on FGEN shares. ]Citigroup Inc.[ restated a \"buy\" rating and issued a $48.00]","prefix":" analysts recently issued reports on FGEN shares. ","exact":"Citigroup Inc.","suffix":" restated a \"buy\" rating and issued a $48.00","offset":2763,"length":14}],"relevance":0.5,"confidence":{"statisticalfeature":"0.999","dblookup":"0.0","resolution":"0.95025086","aggregate":"1.0"}},"http:\/\/d.opencalais.com\/comphash-1\/38a18a1d-c778-3cbe-899a-5edd2266dc5c":{"_typeGroup":"entities","_type":"Company","forenduserdisplay":"true","name":"SG Americas Securities LLC","nationality":"N\/A","confidencelevel":"1.0","confidence":{"statisticalfeature":"0.887","dblookup":"0.0","resolution":"0.40422893","aggregate":"1.0"},"_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/e\/Company","instances":[{"detection":"[in the 2nd quarter valued at about $128,000. ]SG Americas Securities LLC[ increased its holdings in shares of FibroGen by]","prefix":"in the 2nd quarter valued at about $128,000. ","exact":"SG Americas Securities LLC","suffix":" increased its holdings in shares of FibroGen by","offset":4095,"length":26},{"detection":"[shares of FibroGen by 6.5% in the 2nd quarter. ]SG Americas Securities LLC[ now owns 6,747 shares of the biopharmaceutical]","prefix":"shares of FibroGen by 6.5% in the 2nd quarter. ","exact":"SG Americas Securities LLC","suffix":" now owns 6,747 shares of the biopharmaceutical","offset":4195,"length":26}],"relevance":0.5,"resolutions":[{"name":"SG AMERICAS SECURITIES, LLC","permid":"5000019800","ispublic":"false","commonname":"SG Americas Secq","score":0.40422893,"id":"https:\/\/permid.org\/1-5000019800"}]},"http:\/\/d.opencalais.com\/pershash-1\/22443923-5a37-360c-91a2-838557725b2c":{"_typeGroup":"entities","_type":"Person","forenduserdisplay":"true","name":"Pat Cotroneo","persontype":"economic","nationality":"N\/A","confidencelevel":"0.992","firstname":"Pat","lastname":"Cotroneo","commonname":"Pat Cotroneo","confidence":{"statisticalfeature":"0.992","dblookup":"0.0","resolution":"0.8836712","aggregate":"0.992"},"resolutions":[{"name":"Pat Cotroneo","personid":"1765780","paid":"34418285839","officerid":"2101514","commonname":"Pat Cotroneo","score":0.8836712}],"_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/e\/Person","permid":"https:\/\/permid.org\/1-404011","instances":[{"detection":"[Inc (NASDAQ:FGEN) VP ]Pat Cotroneo[ sold 2,851 shares of the business's stock in a]","prefix":"Inc (NASDAQ:FGEN) VP ","exact":"Pat Cotroneo","suffix":" sold 2,851 shares of the business's stock in a","offset":31,"length":12},{"detection":"[which is accessible through the SEC website.\n\n]Pat Cotroneo[ also recently made the following trade(s):\n\nOn]","prefix":"which is accessible through the SEC website.\n\n","exact":"Pat Cotroneo","suffix":" also recently made the following trade(s):\n\nOn","offset":503,"length":12},{"detection":"[ the following trade(s):\n\nOn Tuesday, August 8th, ]Pat Cotroneo[ sold 95,000 shares of FibroGen stock. The shares]","prefix":" the following trade(s):\n\nOn Tuesday, August 8th, ","exact":"Pat Cotroneo","suffix":" sold 95,000 shares of FibroGen stock. The shares","offset":584,"length":12},{"detection":"[of $4,807,950.00. On Wednesday, August 2nd, ]Pat Cotroneo[ sold 28,346 shares of FibroGen stock. The shares]","prefix":"of $4,807,950.00. On Wednesday, August 2nd, ","exact":"Pat Cotroneo","suffix":" sold 28,346 shares of FibroGen stock. The shares","offset":755,"length":12},{"detection":"[of $962,913.62. On Thursday, July 6th, ]Pat Cotroneo[ sold 4,000 shares of FibroGen stock. The shares]","prefix":"of $962,913.62. On Thursday, July 6th, ","exact":"Pat Cotroneo","suffix":" sold 4,000 shares of FibroGen stock. The shares","offset":921,"length":12},{"detection":"[of $136,000.00. On Thursday, June 22nd, ]Pat Cotroneo[ sold 3,000 shares of FibroGen stock. The shares]","prefix":"of $136,000.00. On Thursday, June 22nd, ","exact":"Pat Cotroneo","suffix":" sold 3,000 shares of FibroGen stock. The shares","offset":1087,"length":12},{"detection":"[ transaction of $96,000.00. On Monday, June 19th, ]Pat Cotroneo[ sold 5,500 shares of FibroGen stock. The shares]","prefix":" transaction of $96,000.00. On Monday, June 19th, ","exact":"Pat Cotroneo","suffix":" sold 5,500 shares of FibroGen stock. The shares","offset":1250,"length":12}],"relevance":0.8},"http:\/\/d.opencalais.com\/comphash-1\/84e02fd5-a58b-300f-8a9b-d10ac3cd44ac":{"_typeGroup":"entities","_type":"Company","forenduserdisplay":"true","name":"Jefferies Group LLC","nationality":"N\/A","confidencelevel":"0.999","confidence":{"statisticalfeature":"0.999","dblookup":"0.0","resolution":"0.9612769","aggregate":"0.999"},"resolutions":[{"name":"JEFFERIES GROUP LLC","permid":"8589934268","ispublic":"false","commonname":"Jefferies Group","score":0.9612769,"id":"https:\/\/permid.org\/1-8589934268","ticker":"JEF"}],"_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/e\/Company","instances":[{"detection":"[of FibroGen in a report on Monday, June 26th. ]Jefferies Group LLC[ restated a \"buy\" rating and issued a $75.00]","prefix":"of FibroGen in a report on Monday, June 26th. ","exact":"Jefferies Group LLC","suffix":" restated a \"buy\" rating and issued a $75.00","offset":2891,"length":19}],"relevance":0.5},"http:\/\/d.opencalais.com\/genericHasher-1\/23dadc18-b632-3047-a2a4-41232a548224":{"_typeGroup":"relations","_type":"AnalystRecommendation","forenduserdisplay":"false","financialtrend":"downgraded","rank_new":"neutral","rank_old":"buy","price_new":"$31.00","_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/r\/AnalystRecommendation","company_source":"http:\/\/d.opencalais.com\/comphash-1\/f4a56cd2-94d5-3c7a-8058-1b7297309d15","company_rated":"http:\/\/d.opencalais.com\/comphash-1\/5e2ac775-3229-336a-97ea-8c22044c7324","instances":[{"detection":"[in a report on Saturday, June 24th. Finally, ]Goldman Sachs Group, Inc. (The) downgraded shares of FibroGen from a \"buy\" rating to a \"neutral\" rating and set a $31.00 target price[ for the company. in a report on Friday, July]","prefix":"in a report on Saturday, June 24th. Finally, ","exact":"Goldman Sachs Group, Inc. (The) downgraded shares of FibroGen from a \"buy\" rating to a \"neutral\" rating and set a $31.00 target price","suffix":" for the company. in a report on Friday, July","offset":3297,"length":133}]},"http:\/\/d.opencalais.com\/genericHasher-1\/e0d99917-8784-3bc1-b2c2-705a64a32c7a":{"_typeGroup":"relations","_type":"PersonCareer","forenduserdisplay":"true","position":"VP","careertype":"professional","status":"current","_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/r\/PersonCareer","person":"http:\/\/d.opencalais.com\/pershash-1\/22443923-5a37-360c-91a2-838557725b2c","company":"http:\/\/d.opencalais.com\/comphash-1\/5e2ac775-3229-336a-97ea-8c22044c7324","instances":[{"detection":"[]FibroGen, Inc (NASDAQ:FGEN) VP Pat Cotroneo[ sold 2,851 shares of the business's stock in a]","exact":"FibroGen, Inc (NASDAQ:FGEN) VP Pat Cotroneo","suffix":" sold 2,851 shares of the business's stock in a","offset":0,"length":43}]},"http:\/\/d.opencalais.com\/genericHasher-1\/a16f7f6e-7215-312e-b25e-713cc4861ef9":{"_typeGroup":"relations","_type":"Acquisition","forenduserdisplay":"true","datestring":"Monday, June 19th","status":"announced","confidencelevel":"0.752","_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/r\/Acquisition","company_beingacquired":"http:\/\/d.opencalais.com\/comphash-1\/5e2ac775-3229-336a-97ea-8c22044c7324","instances":[{"detection":"[$32.00, for a total transaction of $96,000.00. ]On Monday, June 19th, Pat Cotroneo sold 5,500 shares of FibroGen stock[. The shares were sold at an average price of]","prefix":"$32.00, for a total transaction of $96,000.00. ","exact":"On Monday, June 19th, Pat Cotroneo sold 5,500 shares of FibroGen stock","suffix":". The shares were sold at an average price of","offset":1228,"length":70}]},"http:\/\/d.opencalais.com\/genericHasher-1\/3dbb1a60-c470-3f84-b784-a67a9d16d7e2":{"_typeGroup":"relations","_type":"CompanyEarningsAnnouncement","forenduserdisplay":"true","quarter":"Q","financialmetric":"EARNINGS Per-Share (Diluted)","_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/r\/CompanyEarningsAnnouncement","permid":"https:\/\/permid.org\/1-1000351539","company":"http:\/\/d.opencalais.com\/comphash-1\/5e2ac775-3229-336a-97ea-8c22044c7324","instances":[{"detection":"[its earnings results on Monday, August 7th. ]The biopharmaceutical company reported ($0.48) earnings per share for the quarter,[ missing analysts' consensus estimates of ($0.47)]","prefix":"its earnings results on Monday, August 7th. ","exact":"The biopharmaceutical company reported ($0.48) earnings per share for the quarter,","suffix":" missing analysts' consensus estimates of ($0.47)","offset":1738,"length":82}]},"http:\/\/d.opencalais.com\/genericHasher-1\/f849fd7d-0a5c-327d-a113-7ac7048ce339":{"_typeGroup":"relations","_type":"CompanyEarningsGuidance","forenduserdisplay":"false","quarter":"FY","financialmetric":"EARNINGS Per-Share (Diluted)","_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/r\/CompanyEarningsGuidance","company":"http:\/\/d.opencalais.com\/comphash-1\/5e2ac775-3229-336a-97ea-8c22044c7324","instances":[{"detection":"[average, equities research analysts expect that ]FibroGen, Inc will post ($1.80) EPS for the current year[.\n\nTRADEMARK VIOLATION NOTICE: \"FibroGen, Inc]","prefix":"average, equities research analysts expect that ","exact":"FibroGen, Inc will post ($1.80) EPS for the current year","suffix":".\n\nTRADEMARK VIOLATION NOTICE: \"FibroGen, Inc","offset":2134,"length":56}]},"http:\/\/d.opencalais.com\/genericHasher-1\/0f0462e9-213c-3d3a-8861-b0e34cb63c3f":{"_typeGroup":"relations","_type":"Acquisition","forenduserdisplay":"true","datestring":"Thursday, July 6th","status":"announced","confidencelevel":"0.752","_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/r\/Acquisition","company_beingacquired":"http:\/\/d.opencalais.com\/comphash-1\/5e2ac775-3229-336a-97ea-8c22044c7324","instances":[{"detection":"[$33.97, for a total transaction of $962,913.62. ]On Thursday, July 6th, Pat Cotroneo sold 4,000 shares of FibroGen stock[. The shares were sold at an average price of]","prefix":"$33.97, for a total transaction of $962,913.62. ","exact":"On Thursday, July 6th, Pat Cotroneo sold 4,000 shares of FibroGen stock","suffix":". The shares were sold at an average price of","offset":898,"length":71}]},"http:\/\/d.opencalais.com\/genericHasher-1\/881ba785-2fb1-3dda-8f4b-32a1cf414c30":{"_typeGroup":"relations","_type":"CompanyTicker","forenduserdisplay":"false","ticker":"FGEN","stockexchange":"NASDAQ","_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/r\/CompanyTicker","company":"http:\/\/d.opencalais.com\/comphash-1\/5e2ac775-3229-336a-97ea-8c22044c7324","instances":[{"detection":"[]FibroGen, Inc (NASDAQ:FGEN)[ VP Pat Cotroneo sold 2,851 shares of the]","exact":"FibroGen, Inc (NASDAQ:FGEN)","suffix":" VP Pat Cotroneo sold 2,851 shares of the","offset":0,"length":27},{"detection":"[firm's market capitalization is $3.73 billion.\n\n]FibroGen (NASDAQ:FGEN)[ last issued its earnings results on Monday,]","prefix":"firm's market capitalization is $3.73 billion.\n\n","exact":"FibroGen (NASDAQ:FGEN)","suffix":" last issued its earnings results on Monday,","offset":1659,"length":22}]},"http:\/\/d.opencalais.com\/genericHasher-1\/d9f9752b-cf03-315f-9754-0443cd765957":{"_typeGroup":"relations","_type":"Acquisition","forenduserdisplay":"true","datestring":"Wednesday, August 2nd","status":"announced","confidencelevel":"0.752","_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/r\/Acquisition","company_beingacquired":"http:\/\/d.opencalais.com\/comphash-1\/5e2ac775-3229-336a-97ea-8c22044c7324","instances":[{"detection":"[for a total transaction of $4,807,950.00. ]On Wednesday, August 2nd, Pat Cotroneo sold 28,346 shares of FibroGen stock[. The shares were sold at an average price of]","prefix":"for a total transaction of $4,807,950.00. ","exact":"On Wednesday, August 2nd, Pat Cotroneo sold 28,346 shares of FibroGen stock","suffix":". The shares were sold at an average price of","offset":729,"length":75}]},"http:\/\/d.opencalais.com\/genericHasher-1\/9db2a436-02c4-3899-8f6d-09807e54749b":{"_typeGroup":"relations","_type":"Acquisition","forenduserdisplay":"true","datestring":"Thursday, June 22nd","status":"announced","confidencelevel":"0.752","_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/r\/Acquisition","company_beingacquired":"http:\/\/d.opencalais.com\/comphash-1\/5e2ac775-3229-336a-97ea-8c22044c7324","instances":[{"detection":"[$34.00, for a total transaction of $136,000.00. ]On Thursday, June 22nd, Pat Cotroneo sold 3,000 shares of FibroGen stock[. The shares were sold at an average price of]","prefix":"$34.00, for a total transaction of $136,000.00. ","exact":"On Thursday, June 22nd, Pat Cotroneo sold 3,000 shares of FibroGen stock","suffix":". The shares were sold at an average price of","offset":1063,"length":72}]},"http:\/\/d.opencalais.com\/genericHasher-1\/541a55a0-3370-31d7-aeb9-687024326a38":{"_typeGroup":"relations","_type":"Acquisition","forenduserdisplay":"true","datestring":"Tuesday, August 8th","status":"announced","confidencelevel":"0.752","_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/r\/Acquisition","company_beingacquired":"http:\/\/d.opencalais.com\/comphash-1\/5e2ac775-3229-336a-97ea-8c22044c7324","instances":[{"detection":"[also recently made the following trade(s):\n\n]On Tuesday, August 8th, Pat Cotroneo sold 95,000 shares of FibroGen stock[. The shares were sold at an average price of]","prefix":"also recently made the following trade(s):\n\n","exact":"On Tuesday, August 8th, Pat Cotroneo sold 95,000 shares of FibroGen stock","suffix":". The shares were sold at an average price of","offset":560,"length":73}]}}